# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001714899-26-000064
Filing Date
2026-05-07
Accepted
2026-05-07 16:12:02
Documents
72
Period of Report
2026-03-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | dnli-20260331.htm iXBRL | 10-Q | 1244548
2 | EX-10.1 | exhibit101outsidedirectorc.htm | EX-10.1 | 54436
3 | EX-10.2 | exhibit102denali_royaltyph.htm | EX-10.2 | 405032
4 | EX-31.1 | exhibit311q12026.htm | EX-31.1 | 9891
5 | EX-31.2 | exhibit312q12026.htm | EX-31.2 | 9911
6 | EX-32.1 | exhibit321q12026.htm | EX-32.1 | 5550
7 | EX-32.2 | exhibit322q12026.htm | EX-32.2 | 5679
| Complete submission text file | 0001714899-26-000064.txt |  | 6430949

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
8 | XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT | dnli-20260331.xsd | EX-101.SCH | 42677
9 | XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT | dnli-20260331_cal.xml | EX-101.CAL | 55832
10 | XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT | dnli-20260331_def.xml | EX-101.DEF | 172535
11 | XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT | dnli-20260331_lab.xml | EX-101.LAB | 550323
12 | XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT | dnli-20260331_pre.xml | EX-101.PRE | 379513
76 | EXTRACTED XBRL INSTANCE DOCUMENT | dnli-20260331_htm.xml | XML | 681130

Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8547
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

EIN.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38311 | Film No.: 26953388
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)